Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis

Anker, Stefan D.; Kirwan, Bridget-Anne; van Veldhuisen, Dirk J.; Filippatos, Gerasimos; Comín Colet, Josep; Ruschitzka, Frank; Lüscher, Thomas F.; rutyunov, Gregory P.; Motro, Michael; Mori, Claudio; Roubert, Bernard; Pocock, Stuart J.; Ponikowski, Piotr

Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis

Mostra el registre complet Registre parcial de l'ítem

dc.contributor.author Anker, Stefan D.ca
dc.contributor.author Kirwan, Bridget-Anneca
dc.contributor.author van Veldhuisen, Dirk J.ca
dc.contributor.author Filippatos, Gerasimosca
dc.contributor.author Comín Colet, Josepca
dc.contributor.author Ruschitzka, Frankca
dc.contributor.author Lüscher, Thomas F.ca
dc.contributor.author rutyunov, Gregory P.ca
dc.contributor.author Motro, Michaelca
dc.contributor.author Mori, Claudioca
dc.contributor.author Roubert, Bernardca
dc.contributor.author Pocock, Stuart J.ca
dc.contributor.author Ponikowski, Piotrca
dc.date.accessioned 2018-05-22T07:31:31Z
dc.date.available 2018-05-22T07:31:31Z
dc.date.issued 2018
dc.description.abstract AIMS: Iron deficiency (ID) is a common co-morbidity in patients with heart failure (HF) and has been suggested to be associated with poor prognosis. Recently completed double-blind randomised controlled trials (RCTs) studying HF patients with ID have shown improvements in functional capacity, symptoms and quality of life when treated with i.v. ferric carboxymaltose (FCM). This individual patient data meta-analysis investigates the effect of FCM vs. placebo on recurrent hospitalisations and mortality in HF patients with ID. METHODS AND RESULTS: Individual patient data were extracted from four RCTs comparing FCM with placebo in patients with systolic HF and ID. The main outcome measures were recurrent cardiovascular (CV) hospitalisations and CV mortality. Other outcomes included cause-specific hospitalisations and death. The main analyses of recurrent events were backed up by time-to-first-event analyses. In total, 839 patients, of whom 504 were randomised to FCM, were included. Compared with those taking placebo, patients on FCM had lower rates of recurrent CV hospitalisations and CV mortality [rate ratio 0.59, 95% confidence interval (CI) 0.40-0.88; P = 0.009]. Treatment with FCM also reduced recurrent HF hospitalisations and CV mortality (rate ratio 0.53, 95% CI 0.33-0.86; P = 0.011) and recurrent CV hospitalisations and all-cause mortality (rate ratio 0.60, 95% CI 0.41-0.88; P = 0.009). Time-to-first-event analyses showed similar findings, with somewhat attenuated treatment effects. The administration of i.v. FCM was not associated with an increased risk for adverse events. CONCLUSIONS: Treatment with i.v. FCM was associated with a reduction in recurrent CV hospitalisations in systolic HF patients with ID.
dc.format.mimetype application/pdf
dc.identifier.citation Anker SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, Comin-Colet J, Ruschitzka F. et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail. 2018 Jan;20(1):125-133. DOI: 10.1002/ejhf.823
dc.identifier.doi http://dx.doi.org/10.1002/ejhf.823
dc.identifier.issn 1388-9842
dc.identifier.uri http://hdl.handle.net/10230/34700
dc.language.iso eng
dc.publisher Wileyca
dc.relation.ispartof European Journal of Heart Failure. 2018 Jan;20(1):125-33
dc.rights © 2017 The Authors. European Journal of Heart Failurepublished by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use anddistribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.subject.keyword Chronic heart failure
dc.subject.keyword Ferric carboxymaltose
dc.subject.keyword Individual patient data meta-analysis
dc.subject.keyword Iron deficiency
dc.subject.other Ferro -- Metabolisme
dc.subject.other Infart
dc.title Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysisca
dc.type info:eu-repo/semantics/article
dc.type.version info:eu-repo/semantics/publishedVersion

Col·leccions

Articles (Hospital del Mar Research Institute)